CCR2 and diabetic kidney disease: For example, selective antagonists of the chemokine receptor CCR2, such as CCX140-B, studied in diabetic mice and tested in clinical trials for patients with diabetic nephropathy (www.clinicaltrials.gov, NCT01447147 and NCT01440257) might be explored for anti-leukemic activity.57